With several decades of combined business experience in the life science and disruptive technology sectors, Norcliffe Capital provides more than capital to support our investments. We use our experience and expertise to select UK based growth companies in our specialist sectors and support them throughout their commercial journey. Operating across the UK and EEA, we source companies with proven IP aiming to make a material impact in their industry, within a growing global market, where there is a clearly defined consumer need. Our investments are usually uncorrelated to the traditional investment markets and have a range of exit routes which offer the potential of generating positive investor returns. Norcliffe Capital works with financial advisers, wealth managers, family offices, private banks, accountants and individuals who are looking to directly invest in innovative UK companies. Our focus is on the life science and disruptive technology sectors with the potential to achieve exponential growth. Norcliffe Capital offers tax efficient ways to invest via the Enterprise Investment Scheme (EIS), SIPP, SSAS or a family investment company, as well as on a direct equity basis. Your capital is at risk. Norcliffe Capital Ltd (FRN # 826977) is an Appointed Representative of Sturgeon Ventures LLP who is authorised and regulated by the Financial Conduct Authority (FRN # 452811)
